SEC Form 6-K filed by argenx SE
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | ||||||||||||||
FORM 6-K | ||||||||||||||
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38097 | ||||||||||||||
| ARGENX SE | ||||||||||||||
| (Translation of registrant’s name into English) | ||||||||||||||
| Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands | ||||||||||||||
| (Address of principal executive offices) | ||||||||||||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ⌧ Form 40-F ☐ | ||||||||||||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐ | ||||||||||||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ | ||||||||||||||
| EXPLANATORY NOTE | ||||||||||||||
On February 26, 2026, argenx SE (the “Company’’) issued a press release, an investor presentation and its full year 2025 unaudited financial results, copies of which are attached hereto as Exhibits 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated by reference herein. | ||||||||||||||
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-292200, 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished. | ||||||||||||||
| EXHIBITS | ||||||||
| Exhibit | Description | |||||||
| 99.2 | ||||||||
| 99.3 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE | ||||||||
| Date: February 26, 2026 | By: | /s/ Hemamalini (Malini) Moorthy | ||||||
| Name: Hemamalini (Malini) Moorthy | ||||||||
| Title: General Counsel | ||||||||